---
title: "HANSOH PHARMA's application for marketing authorization of Dacomitinib Mesylate Tablets has been accepted"
description: "HANSOH PHARMA announced that the group's independently developed innovative drug, methanesulfonate Dacomitinib tablets in combination with methanesulfonate Amivantamab tablets (Amivantamab?) has had i"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/277350918.md"
published_at: "2026-03-01T10:55:19.000Z"
---

# HANSOH PHARMA's application for marketing authorization of Dacomitinib Mesylate Tablets has been accepted

> HANSOH PHARMA announced that the group's independently developed innovative drug, methanesulfonate Dacomitinib tablets in combination with methanesulfonate Amivantamab tablets (Amivantamab?) has had its marketing authorization application accepted by the National Medical Products Administration of China, for the treatment of patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) gene mutation positive who have failed treatment with EGFR tyrosine kinase inhibitors and have mesenchymal-epithelial transition factor amplification

HANSOH PHARMA (03692.HK) announced that the group's independently developed innovative drug, Dacomitinib Mesylate Tablets, in combination with Amivantamab (Amivant), has had its marketing authorization application accepted by the National Medical Products Administration of China for the treatment of patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) gene mutation positive who have failed treatment with EGFR tyrosine kinase inhibitors and have mesenchymal-epithelial transition factor amplification

### Related Stocks

- [159837.CN - E Fund CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159837.CN.md)
- [510660.CN - ChinaAMC SSE Health Care ETF Initiating Fund](https://longbridge.com/en/quote/510660.CN.md)
- [03692.HK - HANSOH PHARMA](https://longbridge.com/en/quote/03692.HK.md)
- [159506.CN - Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF](https://longbridge.com/en/quote/159506.CN.md)
- [516930.CN - Minsheng Royal CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/516930.CN.md)
- [562050.CN - Hwabao WP CSI Pharmaceuticals ETF](https://longbridge.com/en/quote/562050.CN.md)
- [588130.CN - ChinaAMC SSE STAR Biology and Medicine ETF](https://longbridge.com/en/quote/588130.CN.md)
- [512010.CN - E Fund CSI 300 Health Care ETF](https://longbridge.com/en/quote/512010.CN.md)
- [159570.CN - China Universal CNI HK Connect Innovative Drugs Industry ETF](https://longbridge.com/en/quote/159570.CN.md)
- [516500.CN - ChinaAMC CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/516500.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 翰森制药的关键肺癌药物奥莫替尼获得欧盟批准 | 翰森制药获得欧盟对关键肺癌药物阿莫雷替尼的批准 | [Link](https://longbridge.com/en/news/276393466.md) |
| 中国的九源基因正在寻求 Wegovy 生物类似药的批准 | 九源基因生物医药已申请在中国销售其 Wegovy 的生物仿制药版本，正值关键专利到期之前。该公司报告称，其三期临床试验显示，吉可沁在安全性和减重效果上与 Wegovy 具有临床等效性。九源还在寻求 Ozempic 的生物仿制药版本的批准，旨 | [Link](https://longbridge.com/en/news/276994337.md) |
| 翰森制药集团有限公司宣布其单药疗法在欧盟获得批准 | 汉森制药集团有限公司宣布，阿莫雷替尼美克沙片（在中国称为 Ameile）获得欧盟批准，作为单药治疗用于治疗晚期非小细胞肺癌（NSCLC）。这包括针对特定 EGFR 突变的成人患者的首选治疗，以及针对 EGFR T790M 突变阳性 NSCL | [Link](https://longbridge.com/en/news/276480305.md) |
| 在香港上市的中国制药公司有望通过销售增长和交易来实现转机 | 在香港上市的中国制药公司由于药品销售增长和丰厚的许可交易，正准备实现盈利。信达生物预计在 2025 年将首次实现全年的利润，达到 9.84 亿元人民币，主要得益于 45% 的收入增长。百济神州报告净利润为 2.8693 亿美元，得益于其成功 | [Link](https://longbridge.com/en/news/277340041.md) |
| Novo Nordisk 与 Vivtex 达成了一项高达 21 亿美元的合作协议，旨在开发口服肥胖药物 | 丹麦制药公司诺和诺德与美国的 Vivtex 公司达成了一项价值高达 21 亿美元的合作协议，旨在开发用于治疗肥胖和糖尿病的口服药物。诺和诺德将负责全球的开发和商业化，而 Vivtex 将授权其口服药物递送技术。该协议包括一笔未披露的预付款、 | [Link](https://longbridge.com/en/news/276890316.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.